Indian High Court revokes Novartis lung cancer drug patent

28 August 2019

A key cancer drug is set to get cheaper in India with the Delhi High Court revoking the patent on Swiss pharma major Novartis’ (NOVN: VX) ceritinib, marketed as Zykadia.

The Court suspended the earlier interim relief granted to Novartis, which had restrained the manufacture and sale of the generic version of the cancer drug by Natco Pharma (BSE: 524816).

It was only end-May the Delhi High Court had restrained Natco from carrying out any fresh manufacture of drugs comprising the API ceritinib, a non-small cell lung cancer (NSCLC) treatment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK